Literature DB >> 25086620

Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide.

Fatemeh Bagheri1, Shahrokh Safarian, Mohamadreza Baghaban Eslaminejad, Nader Sheibani.   

Abstract

Alterations in expression of the DFF40 gene have been reported in some cancers. This study is an in vitro study of the therapeutic effects of gene transfer that lead to elevation in DFF40 expression within T-47D cells in the presence of sulfonamide drugs. In this study, we have constructed a eukaryotic expression vector for DFF40 and transfected it into T-47D cancer cells. We used real time RT-PCR to detect the expression of DFF40 and the MTT assay to determine effects of the sulfonamide drugs acetazolamide, sulfabenzamide, sulfathiazole and sulfacetamide on cell viability in the presence of increased and normal DFF40 levels. Cell cycle distribution was assessed by propidium iodide (PI) staining and the rates of apoptosis by annexin V/PI staining. The DNA laddering analysis was employed to evaluate apoptosis. We observed that overexpression of DFF40 was only effective in decreasing viability in cells incubated with acetazolamide and sulfabenzamide. There was enhanced apoptosis in these groups, particularly with acetazolamide. The cell cycle distribution analysis showed that in the presence of sulfonamide drugs there were no substantial changes in empty-vector or DFF40-transfected cells, except for those cells treated with sulfabenzamide or sulfathiazole. There was no DNA laddering in cells that expressed the empty vector when incubated with sulfonamide drugs. In contrast, we observed DNA laddering in cells that expressed DFF40 in the presence of acetazolamide. Our results have demonstrated that combinatorial use of some sulfonamides such as acetazolamide along with increased expression of DFF40 can potently kill tumor cells via apoptosis and may be beneficial for treatment of some chemoresistant cancers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25086620      PMCID: PMC5209796          DOI: 10.1007/s11033-014-3626-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  34 in total

1.  Structure of the heterodimeric complex between CAD domains of CAD and ICAD.

Authors:  T Otomo; H Sakahira; K Uegaki; S Nagata; T Yamazaki
Journal:  Nat Struct Biol       Date:  2000-08

Review 2.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

Review 3.  Relatons between structure and biological activity of sulfonamides.

Authors:  T H Maren
Journal:  Annu Rev Pharmacol Toxicol       Date:  1976       Impact factor: 13.820

4.  Death inducing and cytoprotective autophagy in T-47D cells by two common antibacterial drugs: sulphathiazole and sulphacetamide.

Authors:  Raziye Mohammadpour; Shahrokh Safarian; Nader Sheibani; Saeed Norouzi; Atefeh Razazan
Journal:  Cell Biol Int       Date:  2013-03-01       Impact factor: 3.612

5.  Renal carcinoma cells undergo apoptosis without oligonucleosomal DNA fragmentation.

Authors:  Kenya Yamaguchi; Robert Uzzo; Nickolai Dulin; James H Finke; Vladimir Kolenko
Journal:  Biochem Biophys Res Commun       Date:  2004-06-04       Impact factor: 3.575

Review 6.  Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.

Authors:  Claudiu T Supuran; Angela Casini; Andrea Scozzafava
Journal:  Med Res Rev       Date:  2003-09       Impact factor: 12.944

7.  Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.

Authors:  N Celebisoy; F Gökçay; H Sirin; O Akyürekli
Journal:  Acta Neurol Scand       Date:  2007-11       Impact factor: 3.209

8.  A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.

Authors:  Jing-Ping Liou; Kuo-Shun Hsu; Ching-Chuan Kuo; Chi-Yen Chang; Jang-Yang Chang
Journal:  J Pharmacol Exp Ther       Date:  2007-07-27       Impact factor: 4.030

9.  Combined treatment of cisplatin and overexpression of caspase-activated deoxyribonuclease (CAD) promotes apoptosis in vitro and in vivo.

Authors:  Yuichi Kimura; Chizuru Sugimoto; Shigeru Matsukawa; Hiroshi Sunaga; Hideki Igawa; Hideyuki Yamamoto; Toshihisa Ito; Hitoshi Saito; Shigeharu Fujieda
Journal:  Oral Oncol       Date:  2004-04       Impact factor: 5.337

10.  HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y.

Authors:  Hideki Tanaka; Nobuko Ohshima; Mami Ikenoya; Kinuyo Komori; Fumitaka Katoh; Hiroyoshi Hidaka
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

View more
  4 in total

1.  Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40.

Authors:  Fatemeh Bagheri; Shahrokh Safarian; Mohamadreza Baghaban Eslaminejad; Nader Sheibani
Journal:  Biochem Cell Biol       Date:  2015-09-15       Impact factor: 3.626

2.  Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.

Authors:  Tomasz Banas; Kazimierz Pitynski; Krzysztof Okon; Aleksandra Winiarska
Journal:  BMC Cancer       Date:  2018-04-13       Impact factor: 4.430

Review 3.  The role of the DFF40/CAD endonuclease in genomic stability.

Authors:  Merve Kulbay; Nathan Bernier-Parker; Jacques Bernier
Journal:  Apoptosis       Date:  2021-01-02       Impact factor: 4.677

4.  Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.

Authors:  Patrizia Garbati; Raffaella Barbieri; Matilde Calderoni; Francesca Baldini; Mario Nizzari; Paola Modesto; Tullio Florio; Aldo Pagano
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.